Robert Pfotenhauer Joins RxAnte Board of Directors

Share Article

Former UnitedHealth Group Part D CEO adds extensive industry knowledge and new perspectives to leadership team

“RxAnte has proven that its unique analytics platform can help health plans meet their goals of improving medication use and lowering costs."

RxAnte, Inc., a health care analytics company providing an innovative approach to improving medication management, has appointed Robert (Bob) Pfotenhauer to its Board of Directors. Pfotenhauer is the retired CEO of the Medicare Part D business unit of UnitedHealth Group. He brings more than 35 years of health insurance and health care delivery experience to the RxAnte team.

“Bob is incredibly well versed in the day-to-day challenges that health plans face,” said Josh Benner, President and CEO of RxAnte. “His insight will be invaluable in helping us expand our positive impact for these important customers.”

As a member of RxAnte’s Board of Directors, Pfotenhauer will provide strategic insight and guidance on the future direction of the company. Pfotenhauer’s perspective complements the experience of other board members.

“It’s a pleasure to welcome Bob to the Board of RxAnte,” said fellow Director Darren Hite, of RxAnte’s lead investor Aberdare Ventures. “His operating experience and insights will be a great asset to the organization,” Hite added.

“New quality measures are requiring health plans and providers alike to demonstrate improved outcomes,” said Robert Pfotenhauer. “RxAnte has proven that its unique analytics platform can help health plans meet their goals of improving medication use and lowering costs. With health plans viewing patient adherence as a major frontier in cost containment and quality improvement, RxAnte is a leading edge company well positioned to impact this timely issue.”

As a strategic thought leader with skills in executive evaluation and development, finance, operations, and regulatory affairs, Pfotenhauer helped UnitedHealth Group achieve a market leading position against 17 national competitors.

Prior to UnitedHealth Group, Pfotenhauer held executive roles with VISICU, Kaiser Permanente and Group Health Association. He began his career with Group Health Cooperative of Puget Sound in Seattle. He has had extensive experience in start-ups as well as corporate turnarounds.

In addition to his new role at RxAnte, Pfotenhauer also sits on the Board of Directors for Psychiatry Networks. He holds a master’s degree in public health from the University of Michigan program in health services administration.

About RxAnte
RxAnte is a health care improvement company that targets, manages and evaluates medication management programs to improve outcomes and lower costs. The company’s patent-pending predictive analytics and decision support solutions turn ordinary claims data into actionable insights and smart recommendations that help health care organizations and the populations they serve use medications more effectively to improve outcomes and save costs. For more information, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kimberly Hofman-McEnaney
Email >
Visit website